Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

View All Documentation

890810C

Avanti

18:0 DDAB

Avanti Research™ - A Croda Brand 890810C

Sinonimo/i:

Dimethyldioctadecylammonium (Bromide Salt)

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C38H80NBr
Numero CAS:
3700-67-2
Peso molecolare:
630.95
Codice UNSPSC:
12352211
NACRES:
NA.25

Forma fisica

liquid

Confezionamento

pkg of 1 × 2.5 mL (890810C-25mg)
pkg of 2 × 4 mL (890810C-200mg)

Produttore/marchio commerciale

Avanti Research™ - A Croda Brand 890810C

Concentrazione

10 mg/mL (890810C-25mg)
25 mg/mL (890810C-200mg)

Tipo di lipide

cationic lipids
transfection

Condizioni di spedizione

dry ice

Temperatura di conservazione

−20°C

Stringa SMILE

CCCCCCCCCCCCCCCCCC[N+](CCCCCCCCCCCCCCCCCC)(C)C.[Br-]

InChI

1S/C38H80N.BrH/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-39(3,4)38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2;/h5-38H2,1-4H3;1H/q+1;/p-1
PSLWZOIUBRXAQW-UHFFFAOYSA-M

Categorie correlate

Descrizione generale

18:0 DDAB is a cationic lipid and a quaternary ammonium salt. The hydrocarbon tails are saturated, unlike the ionizable lipids. 18:0 DDAB acts as an active nasal adjuvant.

Applicazioni

18:0 DDAB or Dimethyldioctadecylammonium (Bromide Salt) has been used to perform transfection of S2 cells.

Azioni biochim/fisiol

18:0 DDAB is a surface-active molecule, used as an adjuvant to induce a systemic immune response. It is non-toxic.

Confezionamento

5 mL Clear Glass Sealed Ampule (890810C-200mg)
5 mL Clear Glass Sealed Ampule (890810C-25mg)

Altre note

For R&D use only. Not for drug, household, or other uses.

Note legali

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Comunemente ordinati con questo prodotto

N° Catalogo
Descrizione
Determinazione del prezzo

Pittogrammi

Skull and crossbonesHealth hazard
GHS06,GHS08

Avvertenze

Danger

Classi di pericolo

Acute Tox. 3 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 3 - Carc. 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 1 - STOT SE 3

Organi bersaglio

Central nervous system, Liver,Kidney

Classe di pericolosità dell'acqua (WGK)

WGK 3

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Sarah E McNeil et al.
Journal of pharmaceutical sciences, 100(5), 1856-1865 (2011-03-05)
The adjuvanticity of liposomes can be directed through formulation to develop a safe yet potent vaccine candidate. With the addition of the cationic lipid dimethyldioctadecylammonium bromide (DDA) to stable neutral distearoylphosphatidylcholine (DSPC):cholesterol (Chol) liposomes, vesicle size reduces while protein entrapment
Hong Yu et al.
Infection and immunity, 78(5), 2272-2282 (2010-03-17)
Major impediments to developing a Chlamydia vaccine lie in identifying immunologically relevant T-cell antigens and delivery in a manner to stimulate protective immunity. Using an immunoproteomic approach, we previously identified three immunodominant Chlamydia T-cell antigens (PmpG-1, PmpE/F-2, and RplF). Because
Ana Cristina Norberto Oliveira et al.
ACS applied materials & interfaces, 6(9), 6977-6989 (2014-04-10)
This study describes a novel liposomal formulation for siRNA delivery, based on the mixture of the neutral lipid monoolein (MO) and cationic lipids of the dioctadecyldimethylammonium (DODA) family. The cationic lipids dioctadecyldimethylammonium bromide (DODAB) and chloride (DODAC) were compared in
Anne Gallez et al.
International journal of pharmaceutics, 573, 118861-118861 (2019-11-26)
The encapsulation into liposomes of several types of molecules presents the advantages to protect the activity of these molecules and to target specific tissues. Nevertheless, a major obstacle remains the incomplete understanding of nano-bio interactions. Specifically, the impact that inclusion
Hong Yu et al.
Infection and immunity, 80(4), 1510-1518 (2012-02-01)
Major impediments to a Chlamydia vaccine lie in discovering T cell antigens and polarizing adjuvants that stimulate protective immunity. We previously reported the discovery of three T cell antigens (PmpG, PmpF, and RplF) via immunoproteomics that elicited protective immunity in
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.